Bangshun Pharmaceutical files for second Hong Kong IPO attempt

Aug 31, 2026 12:05 (21d ago)

Verifying

Bangshun Pharmaceutical filed a second listing application with the Hong Kong Stock Exchange.
Revenue totaled 943,000 yuan in 2024, 509,000 yuan in 2025 and zero in early 2026.
Bezegratinib received Chinese approval in April 2026 for treating myelofibrosis.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.